Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00032110 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions

DRUG: erlotinib hydrochloride
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)